MoonLake Immunotherapeutics (MLTX) stock
Close on Nov 12, 2026Market cap $1.10BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.10B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.87
- Dividend yield
- –
- Free cash flow yield
- -22.28%
Fundamentals
- Net income
- -$273.48M
- EPS, diluted
- -$3.67
- Free cash flow
- -$244.04M
- Book value per share
- $4.47
- Diluted shares
- 85M
Trading
- Next earnings
- Feb 22, 2027 (estimated, before the open)
- Previous close
- $13.51
- Open
- $13.40
- Day's range
- $12.87 – $13.47
- Volume
- 1,519,291
- Average volume (20 days)
- 1,650,966
- Beta (5 years)
- 0.79
- 52-week range
- $9.46 – $23.29
- RSI (14 days)
- 57.3
- Volatility (1 year)
- 74.4%
- Relative volume
- 1.00×
- WACC
- 8.9%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MLTX | S&P 500 | Difference | MLTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +20.5% | -2.7% | +23.2 pts | ||
| 3 months | -25.3% | -1.7% | −23.6 pts | ||
| Year to date | -2.4% | +11.9% | −14.2 pts | ||
| 1 year | +0.8% | +12.0% | −11.2 pts | ||
| 3 years | -65.8% | +78.2% | −144.0 pts | -30.1% | +21.2% |
| 5 years | +30.1% | +73.2% | −43.1 pts | +5.4% | +11.6% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MoonLake Immunotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
About MoonLake Immunotherapeutics
Pharmaceutical Preparations
MoonLake Immunotherapeutics is a clinical-stage biotechnology company that develops therapies for inflammatory skin and joint disorders. The firm operates as a single-asset entity centered on the clinical evaluation of SLK, an investigational tri-specific Nanobody that inhibits interleukin-17A and interleukin-17F. Its research and development activities target inflammatory conditions within dermatology and rheumatology, primarily hidradenitis suppurativa, psoriatic arthritis, palmoplantar pustulosis, and axial spondyloarthritis. Because its therapeutic candidate remains in clinical development, the company has no commercial sales, and its intended end users are patients suffering from these inflammatory conditions.
Company profile, executives and historyMoonLake Immunotherapeutics stock: common questions
What is MoonLake Immunotherapeutics's stock price?
MLTX closed at $12.87 on Nov 12, 2026, down 4.74% on the day. Over the past 52 weeks it traded between $9.46 and $23.29.
What is MoonLake Immunotherapeutics's market cap?
MoonLake Immunotherapeutics was worth $1.10B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MLTX's P/E ratio?
MoonLake Immunotherapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.67), so it has no meaningful P/E ratio.
Does MoonLake Immunotherapeutics pay a dividend?
No. MoonLake Immunotherapeutics has not paid a cash dividend over the last twelve months.
When does MoonLake Immunotherapeutics report earnings next?
MoonLake Immunotherapeutics is expected to report Q4 FY2026 results on Feb 22, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MLTX stock performed over the past year?
Including dividends, MLTX returned +0.8% over the past year, against +12.0% for the S&P 500.
How many MLTX shares are sold short?
5M shares were sold short at the latest FINRA report, 16.05% of the float, or 2.9 days of average trading volume.
Who are MoonLake Immunotherapeutics's competitors?
Companies most similar to MoonLake Immunotherapeutics by business, industry and size include AVTX, ACRS, SYRE, CLYM, CRVS.
See a number that looks wrong?